Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1

2(40.0%)

Phase 3

2(40.0%)

Phase 2

1(20.0%)

5Total

Phase 1(2)

Phase 3(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT01068912Phase 2Completed

Dose-Finding Study of Favipiravir in the Treatment of Uncomplicated Influenza

Role: lead

NCT02026349Phase 3Completed

Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults - T705US316

Role: lead

NCT02008344Phase 3Completed

Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults

Role: lead

NCT01419457Phase 1Completed

Pharmacokinetics of Favipiravir in Volunteers With Hepatic Impairment

Role: lead

NCT01728753Phase 1Completed

T-705a Multicenter Study in Adults Subjects With Uncomplicated Influenza

Role: lead

All 5 trials loaded